CIMS Fever Clinic

CIMS Fever Clinic

JCI

JCI

Isolation Unit

Isolation Unit

CIMS BREAST CANCER

CIMS BREAST CANCER

Global Healthcare Excellence Award 2018

Global Healthcare Excellence Award 2018

Diabetes Check

Diabetes Check

Trials

Research at CIMS


CIMS Research Center, which has been participating in the Clinical trials since more than a decade & having experience of more than 120 trials (phase III,phase lV,registries and device).The CIMS Research center is well established department which offers suitable infrastructure as per the clinical industry norms, highly experienced team of Doctors & full time clinical research coordinators dedicated to conduct the clinical trials flawlessly.

We are having experience of conducting clinical trials in various therapeutics areas like Cardiology, Pulmonology, Oncology, Orthopedics, & Gastroenterology.

Clinical Trials

  1. RUBY registry (For India) (2002). To evaluate Percusurge / Guardwire Distal Protection Device (Presented by Dr. Aman, Switzerland). Presented TCT October 2003, Sponsored by Medtronics Pvt. Ltd. Study Completed.
  1. Extract-TIMI 25 Multicentre multinational Trial (2003). Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction –Study 25. Presented at ACC 06. Study Completed.
  1. To Evaluate the Efficacy and Safety of Fondaparinux versus Enoxaparin in the Acute Treatment of Unstable Angina or Non ST-Segment Elevation Myocardial Infarction Acute Coronary Syndromes. Presented in ESC, Stockholm, Sweden.Study Completed.
  1. OASIS-6 Trial (2004). To Evaluate the Efficacy and Safety of Fondaparinux Sodium versus Control Therapy and Glucose-Insulin-Potassium Infusion versus Control in Broad Range in Patients with ST -Segment Elevation Acute Myocardial Infarction. Presented at ACC 06. Trial Complete
  1. TRUST Trial (2004). To Evaluate the Safety and Efficacy of Intravenous Remodulin® in Patients (in India) with Pulmonary Arterial Hypertension (PAH) in 12-week. Study Completed.
  1. Paediatric Hypertension Trial (2005). Dose Ranging Study to Evaluate the Safety and Efficacy of Olmesartan medoxomil in Children and Adolescents with Hypertension. Study Completed.
  1. Hypercholesterol study (NK-104-301) at The Heart Care Clinic/CIMS (2005). Study of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients with Primary Hypercholesterolemia or Combined Dyslipidemia. Study Completed.
  1. Neovasc Reducer™ Pilot Study, First in human: (2005). To Evaluate the Safety of the Neovasc Reducer™ in the Treatment of Ischemic Heart Disease (IHD) Controlled Narrowing of the Coronary Sinus. Presented at TCT, 2005. Study Completed.
  1. PAPIRUS Trial: Pilot Study, First in Human: Apollo Hospital (2005). Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (REMON Device). Study Completed.
  1. Export study (2006). Flow Improvement in Patients with Acute Myocardial Infarction Undergoing Either Conventional Stenting or a Strategy of Primary Aspiration Followed by Stenting Using the Export® Aspiration Catheter: a Prospective, Randomized, Controlled Study. Study Completed.
  1. Five registry (for India) (2006). To Evaluate the ‘Real World’ Clinical Performance of the Medtronic Endeavor™ ABT-578 Eluting Coronary Stent System. Study Completed.
  1. RELY study (2006). Randomized Evaluation of Long Term Anticoagulant Therapy Comparing Efficacy and Safety of Two Blinded Doses of Dabigatran etexilate with Open Label Warfarin for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation : Prospective, Multi-Centre, Parallel Group, Non-Inferiority Trial. Study Completed.
  1. RELY ABLE study (2009). Long Term Multi-center Extension of Dabigatran Treatment in Patients with Atrial Fibrillation Who Completed the RELY Trial and a Cluster Randomized Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes. Study Completed.
  1. Hypercholesterolemia study (NK-104-307) at The Heart Care Clinic/CIMS (2006). Open Label, Long-Term (1year) Extension Study of Pitavastatin 4 mg QD in Patients with Primary Hypercholesterolemia or Combined Dyslipidemia. Study Completed.
  1. e-SELECT Registry (2007). The e-SELECT Registry: A Multicenter Post Marketing. Study Completed.
  1. Early ACS trial (2007). Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS). Study Completed.
  1. PLATO trial (2007). A Randomized, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of AZD6140 Compares with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO – A study of Platelet inhibition and Patient Outcomes.] Study Completed.
  1. OASIS- 7 trial (2007). Randomized, Multinational, Double-blind study, comparing a High Loading Dose Regimen of Clopidogrel versus Standard Dose in Patients with Unstable Angina or Non-ST Segment Elevation Myocardial Infarction Managed with an Early Invasive Strategy. Study Completed.
  1. New Guidewire (2007). First in Man: A Feasibility Study to Evaluate Safety and Efficacy of New Guidewire for Crossing Total Occlusions in Coronary Arteries. Study Completed.
  1. Paediatric Hypertension Trial, the Heart Care Clinic/CIMS, Ahmedabad (2007). A Randomized, Double blind, Placebo-Controlled, Multicenter, Parallel Study Assessing the Efficacy, Safety, and Dose Response of Ramipril for the Treatment of Hypertension in Children and Adolescents. Study Completed.
  1. Aristotle Trial at The Heart Care Clinic/CIMS, Ahmedabad (2007). Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation: Active Controlled Randomized Double Blind Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Subject with Non-valvular Atrial Fibrillation. Study Completed.
  1. Rocket Trial at The Heart Care Clinic/CIMS, Ahmedabad (2007). Multicenter, Randomized, Double-blind – Dummy, Parallel-group, Non-inferiority Trial Comparing the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-dose Oral Warfarin for the Prevention of Stroke and Non-central-nervous-system Systemic Embolism in Subjects with Non-valvular Atrial Fibrillation. Study Completed.
  1. PROTECT Trial (2007). Patient Related Outcomes with Endeavor versus Cypher Stenting Trial: Prospective, Multicenter, Randomized, Two-arm, Open-label Trial. Study Completed.
  1. TMC-CAN-05-02 (2007). A Clinical Trial Comparing Cangrelor to Clopidogrel in Subject who Require Percutaneous Coronary Intervention. Study Completed.
  1. TMC-CAN-05-03 (2008). A Clinical Trial Comparing Treatment with Cangrelor (in combination with usual care) to Usual Care in Subjects who Require Percutaneous Coronary Intervention. Study Completed.
  1. RELY AF Registry (2008).: Risk Factors, Treatments and Outcomes for Emergency Department Patients with Atrial Fibrillation in Multiple Regions of the World. Study Completed.
  1. CL (Ivabradine) at the Heart Care Clinic/CIMS (2008). Evaluation of the Anti-anginal Efficacy. Study Completed.
  1. RE-DEEM at The Heart Care Clinic/CIMS (2008). Randomized Dabigatran Etexilate Dose Finding Study in Patients with Acute Coronary Syndromes Post Index Event with Additional Risk Factors for Cardiovascular Complications also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, and Group Dose Escalation Trial. Study Completed.
  1. Magellan Trial (2008). A Multicenter, Randomized, Parallel-group Efficacy Superiority Study in Hospitalize Medically Ill Patients Comparing Rivaroxaban with Enoxaparin. Study Completed.
  1. Borealis Trial at the Heart Care Clinic/CIMS Ahmedabad (2008). A Multicenter, Randomized, Double-blind, Assessor-blind, Non-inferiority Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) with Oral Adjusted-dose Warfarin in the Prevention of Stroke and Systemic Thromboembolic Events in Patient with Atrial Fibrillation. Study Completed.
  1. Freedom-PAH at The Heart Care Clinic/CIMS. FREEDOM UT –15C Studies (TDE-PH-302 and TDE-PH-304) Conducted by United Therapeutics. Follow ups Ongoing.
  1. ORBIT – 1. Pilot Study to Evaluate the Safety & Performance or the Diamondback 360TM Orbit Atherectomy System in Treating De Novo Calcified Coronary Lesions – Orbit –I. Study Completed.
  1. AVERROES at the Heart Care Clinic/CIMS. CV 185-048: A Phase 3, Active (Aspirin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate the Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation. Study Completed.
  1. Red-HF at The Heart Care Clinic/CIMS. A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia –. Study Completed.
  1. TAK-442-202 at the Heart Care Clinic/CIMS. A Phase II, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of TAK-442 in Subjects with Acute Coronary Syndrome. Study Completed.
  1. EISAI-202 at The Heart Care Clinic/CIMS. A Randomized, Double-Blind Placebo Controlled Study of the Safety and Tolerability of E5555 and its Effect on Clinical Event and Biomarkers in Patient with Non-ST Segment Elevation Acute Coronary Syndrome. Study Completed.
  1. E-Resolute at the Heart Care Clinic/CIMS. Evaluation of the Endeavor Resolute Zotarolimus -Eluting Coronary Stent System in a ‘Real World’ Patient Population. Follow-up ongoing
  1. RIVAROXABAN at The Heart Care Clinic/CIMS. Randomized, Double Blind, Placebo Controlled, Event Driven, Multi-Center Study To Evaluate The Efficacy And Safety of Rivaroxaban in Subjects With Recent ACS. Study Completed.
  1. Pfizer PAH at The Heart Care Clinic/CIMS B1321001. A Phase 3, Multi-center, Randomized, Double Blind, Placebo Controlled, Safety and Efficacy Study of Sitaxsentan Sodium in Subjects with Pulmonary Arterial Hypertension. Study Completed.
  1. Pfizer PAH at The Heart Care Clinic/CIMSB1321002. A Phase 3, Multi Center, Open Label Study To Evaluate The Long Term Safety of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension. Study Completed.
  1. Pfizer PAH at The Heart Care Clinic/CIMSB1321003. A Phase 3, Multi Center, Randomized, Double Blind, Efficacy and Safety Study of Monotherapy Sitaxsentan Sodium versus Combination Therapy with Sitaxsentan Sodium and Sildenafil Citrate in Subjects with Pulmonary Arterial Hypertension who have Completed Study B1321001. Study Completed.
  1. LPL STABILITY at The Heart Care Clinic/CIMS. A Clinical Outcome Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Event (MACE).Study Completed.
  1. OASIS-8 at The Heart Care Clinic/CIMS. A Prospective Study Evaluating the Safety of Two Regimens of Adjustive Intravenous UFH PCI in High Risk Patients with UA/NSTEMI Initially Treated with Subcutaneous Fondaparinux and Referred for Early Coronary Angiography. Study Completed.
  1. STEM CELL. A Randomized, Double Blind, Multi Centric, Placebo Controlled, Single Dose, Phase I/II Study Assessing the Safety and Efficacy of Intravenous Ex Vivo Cultured Adult Allogenic Mesenchymal Stem Cell in Patients with ST Elevated Acute MI (STEMI). Study Completed.
  1. RUBY 1Trial at The Heart Care Clinic /CIMS Ahmedabad (2010). A Randomized, Double Blind, Placebo Controlled, Multicentre and Parallel Group Study of the Safety, Tolerability, and Efficacy of YM150 in Combination with Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects with Acute Coronary Syndromes. Study Completed.
  1. AmarinTrial at The Heart Care Clinic/CIMS Ahmedabad (2010). A phase 3, Multi centre, Placebo Controlled, Randomized, Double Blind, 12 Week Study with an Open Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients with Fasting Triglyceride Levels > 500 mg/dl and < 2000 mg/dl. Study Completed.
  1. AppraiseTrial at The Heart Care Clinic/CIMS Ahmedabad (2010). A Phase III, Randomized, Double Blind, Evaluation of the Safety and Efficacy of Apixaban in Subjects with a Recent Acute Coronary Syndrome. Study Completed.
  1. SAS HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2008). South Asian Systolic Heart Failure Registry. Study Completed.
  1. TRAC HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). TRAC HF: Ambulatory Monitoring Using External Physiological Sensors in Heart Failure Patients. Study Completed.
  1. DOT HF Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). DOT-HF- Diagnostic Outcome Trial in Heart Failure. Study Completed.
  1. T BEST D Trial at The Heart Care Clinic/CIMS Ahmedabad (2009). T-BEST-D: Temporary Bronchial Epicardial Stimulation – Defibrillation Clinical Study Version dated: June 28, 2009. Study Completed.
  1. ALECARDIO Trial at The Heart Care Clinic/CIMS Ahmedabad (2010). A phase 3 Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study Cardiovascular Outcome Study to Evaluate the Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients with a Recent Acute Coronary Syndrome ( ACS) Event and Type 2 Diabètes Mellites (T2D). Study Completed.
  1. TIMI 52 Trial at The Heart Care Clinic / CIMS Ahmadabad (2010). A Phase 3 Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study of Darapladib versus Placebo in Subject Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events. Study Completed.
  1. SOLISTICE trial at CIMS Hospital Ahmadabad (2011). A Randomized ,Double-blind, Placebo-controlled Study to Evaluate the Safety of 12 Weeks of Dosing with GW856553 and its Effects on Inflammatory Markers, Infract Size, and Cardiac Function in Subjects with Myocardial Infarction without ST Segment Elevation. Study Completed.
  1. CANVAS study at CIMS Hospital Ahmadabad (2011). A Randomized. Double-blind, Parallel, Placebo-Controlled, Multicenter Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus. The CANVAS Trial (Canaagliflozin cardioVascular Assessment Study). Follow up Ongoing
  1. ATTAIN at CIMS Hospital Ahmadabad (2011). A Prospective, Non-randomized, Multi-center, Post-market, Global Clinical Trial to Assess Left-heart Lead Implant and Complication Rate Using the Medtronic Attain Family of Left-heart Leads and Delivery Catheters. Study Completed.
  1. TIMI 53 at CIMS Hospital Ahmadabad (2011). A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Sexagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patient with Type 2 Diabetes. Study Completed.
  1. OPTIMIND at CIMS Hospital Ahmadabad (2011). Clinical Outcome of Pacemaker Patients According to Pacing Modality and Primary Indications. Study Completed.
  1. SST at CIMS Hospital Ahmadabad (2011). The Pain Free SST (Smart Shock Technology) Clinical Study. Study Completed.
  1. VISTA 16 study at CIMS Hospital Ahmedabad (2011). Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with Acute Coronary Syndrome (ACS). VISTA-16: Vascular Inflammation Suppression to Treat Acute coronary syndrome for 16. Study Completed.
  1. TAO study at CIMS Hospital Ahmedabad (2011). Randomized, Double-blind, Triple-dummy Trial to Compare the Efficacy of Otamixaban with Unfractionated Heparin + Eptifibatide, in Patients with Unstable Angina/Non ST Segment Elevation Myocardial Infarction Scheduled to Undergo an Early Invasive Strategy”. Study Completed.
  1. APOLLO study at CIMS Hospital Ahmedabad (2011). A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People Aliskiren Prevention of Later Life Outcomes (APOLLO). Study Completed.
  1. DELIVER study at CIMS Hospital Ahmedabad (2011).Deliverability of Resolute Integrity Stent In all- Comer Vessels and Cross over Stenting”. Study Completed.
  1. EPICOR ASIA study at CIMS Hospital Ahmedabad (2011). Long term follow up of antithrombotic management patterns In Acute coronary Syndrome patients in Asia. Study Completed.
  1. REMOTE-EVIA study at CIMS Hospital Ahmedabad (2011). Registry for Pacemaker Offering Therapy Enhancement- EVIA. Study Completed.
  1. ABSORB Extend (2011) A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the treatment of Subjects with de novo Native Coronary Artery Lesions. Study Completed.
  1. IHRS study at CIMS Hospital Ahmedabad (2011). Indian Heart Rhythm Society (IHRS) Registry of Atrial Fibrillation: Patient Characteristics and Clinical Management Practices. Study Completed.
  1. SureScan Pacing System Post-Approval Study at CIMS Hospital, Ahmedabad (2012). Study Completed.
  1. BISO-CAD (2012). A study to investigate the association between resting heart rate (HR) and prognosis of patients with Coronary Artery Disease (CAD) treated with bisoprolol. Study Completed.
  1. IMPROVE-Brady study at CIMS Hospital, Ahmedabad (2012). Recruitment Ongoing.
  1. Medtronic Symplicity (2013) HTN-INDIA (CIP: 10054637DOC): Single-arm Study of Symplicity™ Renal Denervation System in Patients with Uncontrolled Hypertension in India – HTN-India. Study Completed.
  1. Panorama 2 Registry at CIMS Hospital, Ahmedabad (2012). Medtronic CRDM Implantable Cardiac Device Long Term Registry. Study Completed.
  1. CAD-PAD Registry at CIMS Hospital, Ahmedabad (2013). Coronary and Peripheral Artery Disease Registry. Study Completed.
  1. A Double-blind, Randomized, Placebo controlled, multicenter study assessing the impact of additional LDL-Cholesterol reduction on Major cardiovascular events when AMG 145 is used in combination with statin therapy in patients with clinically evident cardiovascular disease. Study Completed
  1. To Evaluate The Role Of Radiation Protection Technology (CardiotrapTM) In Improving Radiation Safety In Diagnostic And Interventional Percutaneous Cardiology Procedures. Investigator Initiated Study. Recruitment Ongoing
  1. Safety and Efficacy of Axiostat® hemostatic dressing on radial access after percutaneous procedure: A comparative open label study. Investigator Initiated Study. Recruitment Ongoing.
  1. A Phase III, International, Multi-Centre, Randomized, Double-Blinded, Placebo-Controlled, Clinical Worsening study of UT-15C in Subjects with Pulmonary Arterial Hypertension Receiving Background oral Monotherapy (PH-310/11). Recruitment Ongoing
  1. An Open-Label Extension study of UT- 15C in subjects with Pulmonary Arterial Hypertension – A Long-Term Follow up to Protocol TDE-PH-304. Follow up Ongoing.
  1. A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus. Follow up Ongoing
  1. A multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes. Follow up Ongoing.
  1. TWILIGHT-Ticagrelor with Aspirin or alone in high risk patients after coronary intervention. Follow up Ongoing
  1. REDUAL-PCI at CIMS Hospital, Ahmedabad (2014). A prospective Randomised, open label, blinded endpoint (PROBE) study to Evaluate DUAL antithrombotic therapy with dabigatran etexilate (110mg and 150mg bid.) plus clopidogrel or ticagrelor vs. triple therapy strategy with warfarin (INR 2.0 – 3.0) plus clopidogrel or ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting (RE-DUAL PCI). Study Completed.
  1. Asian HF Registry at CIMS Hospital Ahmedabad (2012) Asian Sudden Cardiac Death in Heart Failure Recruitment Ongoing
  1. PRISM at CIMS Hospital, Ahmedabad (2012). A Prospective Multi-Centre Registry to Investigate Safety and Effectiveness of M’Sure-S (Sirolimus Eluting Coronary Stent). Follow up Ongoing
  1. E Resolute Asia at CIMS Hospital, Ahmedabad (2010). Evaluation of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a Patient Population with Long Lesion(s) and/or Dual Vessels in Asia; Prospective, Multi-center, Non-randomized Study. Study Completed.
  1. INSPIRE-ELR at CIMS Hospital, Ahmedabad (2013). – IdeNtifying High riSk Patients Post Myocardial Infarction with REduced Left Ventricular Function using External Loop Recorders. Follow up Ongoing
  1. Improve SCA at CIMS Hospital, Ahmedabad (2014). For Improve Sudden Cardiac Arrest study. Study Completed.
  1. REPORT HF at CIMS Hospital, Ahmedabad (2014).International Registry to assess mEdical Practice with lOngitudinal obseRvation for Treatment of Heart Failure. Follow up Ongoing.
  1. LUX- Head & Neck 2: A randomized, double blind, placebo- controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma. Study Completed.
  1. LUX- Head & Neck 2: A randomized, double blind, placebo- controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa or IVb loco-regionally advanced head and neck squamous cell carcinoma. Study Completed.
  1. A 52-week treatment, multi-center, randomized, double blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD” Study Number: Study Completed.
  1. A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compared with tiotropium on Chronic Obstructive Pulmonary Disease (COPD) exacerbation in patients with severe to very severe COPD. DYNAGITO, Study Completed
  1. A 24-week, double-blind, randomized, parallel group study evaluating the efficacy and safety of oral nintedanib co-administered with oral sildenafil, compared to treatment with nintedanib alone, in patients with idiopathic pulmonary fibrosis (IPF) and advanced lung function impairment. Follow up Ongoing
  1. A 52-week, multicenter, randomized, double-blind, placebo controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma. Recruitment Ongoing
  1. MORE CRT: MOre REsponse on Cardiac Resynchronization Therapy (CRT) with Multipoint Pacing (MPP). Recruitment Ongoing.
  1. ADVANCE CRT :  ADVANCE CRT REGISTRY. Study Completed.
  1. PFIZER CANCER : A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab* (Msb0010718c) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-Line Platinum-Containing Chemotherapy. Recuitment Ongoing
  1. BIVAFLO Registy (2006). To evaluate the Efficacy and Safety of BIVAFLO® as an Adjunctive Therapy During PCI in Moderate-high Risk ACS Patients with Provisional GP IIb/IIIa Inhibitors Use. (Completed)
  1. CORREL + C Trial (2006). The COREL C Registry: A Multicentre Post Marketing Surveillance for Clinical and Angiographic Evaluation of Corel C Stent. (Completed)
  1. POLYCAP Trial at The Heart Care Clinic/CIMS Ahmedabad (2007). A Randomized Double blind controlled trial of the efficacy And safety of POLYCAP Vs its components in subjects With at least one additional cardiovascular risk factor. (Completed)
  1. ACUNOVA Trial (2006-2007). A phase III, open label, multi-centric, parallel group, Randomized study to evaluate the safety and efficacy of Abciximab in Indian patients scheduled for Percutaneuos Coronary Intervention. (Completed)
  1. ZYHI Trial at The Heart Care Clinic Ahmedabad (2007) Study Completed.
  1. “The Dyslipidemia REMAINS Study” – A multicenter, prospective, observational study of lipid profiles and treatment patterns at presentation and after 12 weeks of statin therapy among Indian adults presenting with first coronary event, ongoing at CIMS Hospital Ahmedabad (2012). Study Completed
  1. HF-Registry at CIMS Hospital, Ahmedabad (2012). A prospective, open label, multi-centric, observational registry for heart failure patients across India. Study Completed
  1. “The International Polycap Study 3” (TIPS 3) at CIMS Hospital, Ahmedabad (2012) – A randomized double-blind placebo-controlled trial for the evaluation of a polycap, low dose aspirin and vitamin D supplementation in primary prevention. Follow up Ongoing.
  1. BioMime Morph at CIMS Hospital, Ahmedabad (2016). A prospective, single-arm, multi-centre, observational, real world, post-marketing surveillance to evaluate safety and performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for very long coronary lesions. Recruitment Ongoing
  1. TREASURE at CIMS Hospital, Ahmedabad (2015).A non-inTeRventional prospEctive observationAl Study to understand the usage pattern of Ticagrelor in Indian patients with acute coronaRy syndromE (TREASURE). Study Completed
  1. A Prospective, Randomized, Multi-Center Study to Compare the safety, Tolerability and Efficacy of Bevacizumab (Zydus Cadila) with Bevacizumab (Avastin ®) in Non-Small Cell Lung Cancer (NSCLC). Completed
  1. BIO-REPOSITORY – Collection of tumor tissue, serum sample and associated data from patients of various malignancies. Study Completed
  1. PAREXEL COPD : 24-week Treatment, Randomised, Parallel-group, Double blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium bromide/Formoterol fumarate compared with Individual Components and Placebo and Aclidinium bromide compared with Placebo when Administered to Patients with Stable Chronic Obstructive Pulmonary Disease [AVANT study]
  1. Protocol Title: A multi-center, randomized, 12-week treatment, double blind study to assess the efficacy and safety of QMF149 (150/80 microgram) compared with MF Twisthaler® (200 microgram) in adult and adolescent patients with asthma. Recruitment Ongoing.
  1. Protocol Title: An Open Label, Single Arm, Multicentric, Phase IV study to evaluate the safety and efficacy of Bevacizumab of Intas Pharmaceuticals Limited in approved indications. Recruitment Ongoing.
  1. Protocol Title: A phase iv, open label, multi-center study for safety evaluation of Apixaban in Indian participants undergoing elective total knee replacement or total hip replacement surgery. Recruitment Ongoing.
  1. Protocol Title: Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients with Chronic Heart Failure with Reduced Ejection Fraction : Recruitment Ongoing.
Web Design MymensinghPremium WordPress ThemesWeb Development

CIMS GlobL Healthcare Excellence Awards 2018

October 30, 2018
CIMS Family is honoured to be the recipient of “Among Best Hospital (Cardiology & Oncology) in Gujarat” on October 27, 2018 at the “Prime Time Global Healthcare Excellence Awards 2018”, New Delhi. A very special thanks to our CIMS Staff for their commitment and the patients who have always trusted us. CIMS GlobL Healthcare Excellence Awards 2018

CIMS Hospital has been awarded the Certificate of Excellence as the Best Multispecialty Hospital in Gujarat

August 31, 2018
We proudly announce that CIMS Hospital has been awarded the Certificate of Excellence as the Best Multispecialty Hospital in Gujarat at the International Healthcare Awards, 2018 held in Delhi. The Award is a testimony to the hard work and dedication of the entire CIMS Family which has inspired trust in us leading to rising patient volumes.

Certificate course in EMG & NCV Technology

May 15, 2018

Renal Transplant (CIMS/RIC/2018/09) on 15/05/2018

May 15, 2018
Renal Transplant is done on 15/05/2018, which was approved by Hospital based Ethical committee and Government Authorization committee. Relationship between Donor and Recipient : Wife - Husband

We are proud to announce that CIMS Hospital has been recognized as the Times Health Icon 2018 in 2 categories

March 19, 2018
We are proud to announce that CIMS Hospital has been recognized as the Times Health Icon 2018 in 2 categories Multispecialty Hospital- Oncology and Multispecialty Hospital-Critical Care.

CIMS Heart Transplant Team completes another successful Heart Transplant on 06-02-2018, 5th row in a short term.

February 8, 2018

Felicitation Ceremony of Heart Transplant Donors and Recipients held in the presence of Honorable Chief Minister of Gujarat, Shri Vijay Rupani, CIMS cardiac and heart tranplantation doctors by CIMS Hospital.

January 12, 2018
Felicitation Ceremony of Heart Transplant Donors and Recipients held in the presence of Honorable Chief Minister of Gujarat, Shri Vijay Rupani, CIMS cardiac and heart tranplantation doctors by CIMS Hospital.